clinical trial · NCT04886531
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Ruth O'Regan·phase2·recruiting·n = 30
Breast CancerHER2-positive Breast CancerER Positive Breast CancerPR-Positive Breast CancerNeratinibLetrozole (L) or Anastrozole (A)Trastuzumab
brief summary
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of week 4 of treatment. Following surgery, patients will receive standard of care HER2-directed and endocrine therapy at the treating physician's discretion.
started
Jul 21, 2022
primary completion
Jun 22, 2026
completion
Jul 21, 2027
last updated
Apr 8, 2026
official title
An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Cancers Hoosier Cancer Research Network BRE17-141
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol